CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology, Inc. Common stock

CG Oncology is a privately held oncolytic immunotherapy company focused on developing bladder-saving therapeutics for patients with bladder cancer. At CG Oncology we see a world where urologic cancer patients can benefit from our innovative therapies to live and work with dignity and an enhanced quality of life.

Our lead candidate, CG0070, is an intravesically delivered oncolytic immunotherapy agent in a Phase 3 trial for the treatment of BCG-unresponsive non-muscle invasive bladder cancer. CG0070 is also in a Phase 2 study in combination with KEYTRUDA® (pembrolizumab) in the same indication. Other types of bladder cancer are being evaluated with CG0070 in combination with OPDIVO® (nivolumab).

Whitesun Healthcare Ventures

WI Harper Group

Song Hong Fang

Ally Bridge Group

ORI Capital

Perseverance Capital Management

Camford Capital

Kissei Pharmaceutical

Decheng Capital

RA Capital Management

Sirona Capital

Acorn Bioventures

Longitude Capital

Malin Corporation

Foresite Capital

BVF Partners

TCG Crossover

Avidity Partners

Janus Henderson Investors

CG Oncology

Join Dr. Vijay Kasturi, CG Oncology’s Chief Medical Officer, at the 2024 American Urological Association (AUA) Annual Meeting in #SanAntonioTX. Dr. Kasturi will share how CG Oncology is advancing the fight against bladder cancer with innovative solutions at our booth #100 from May 3-5 at 12:30 pm CDT. He will provide insights into our pipeline, clinical trials, and the potential of cretostimogene grenadenorepvec as a therapeutic option.

📅 May 3-5, Booth #100
⏰ 12:30 pm (10 to 15 mins) 

Our team is looking forward to sharing our latest advancements for #NMIBC patients.

👉 More on the event here: auanet.org/AUA2024

#CGOncology #BladderCancer #UroOncology #CancerResearch #ClinicalTrial #Therapeutics #DrugDevelopment #Immunotherapy #TherapeuticAdvances #AUA24

Each year, more than 80,000 people in the United States receive a #bladdercancer diagnosis. 🩺

CG Oncology is committed to addressing the unmet needs of these patients and focused on developing bladder-saving therapeutics. Join us in the Bladder Cancer Advocacy Network (BCAN) 2024 Walks to End Bladder Cancer, happening all across the country. These walks are a celebration of hope as we unite to advance research and provide support for patients and their loved ones. 

👉 Find a walk near you at https://bit.ly/3x65qD3 

#CGOncology #EndBladderCancer #BladderCancerAwareness #BladderCancer #UroOncology #CancerResearch #MedicalResearch #CancerSupport #BCANWalk2024 

CG Oncology is excited to share our updated results on cretostimogene grenadenorepvec at the 2024 American Urological Association (AUA) Annual Meeting in San Antonio, TX from May 3-6, 2024.  

Dr. Robert Svatek of UT Health San Antonio and Dr. Mark Tyson, M.D., M.P.H of Mayo Clinic Scottsdale, AZ, will present abstracts highlighting cretostimogene, while an oral presentation will feature the interim 12-month Phase 3 data from the BOND-003 trial. If you are attending #AUA2024, we invite you to join us and meet our team at booth #100. Cretostimogene has the potential to be a backbone therapy for patients diagnosed with bladder cancer. 

📖 For more information, read the full release: https://bit.ly/3PEUbI0 

#CGOncology #BladderCancer #CancerResearch #UroOncology #MedicalResearch #CancerResearch #ClinicalTrial #Therapeutics #DrugDevelopment #Immunotherapy #OncologyBreakthrough #TherapeuticAdvances #AUA24

🧬 Excitement is building for #AUA2024! Join us at the 2024 American Urological Association (AUA) Annual Meeting, taking place in #SanAntonioTX from May 3-6.

Meet CG Oncology’s Medical Team at Booth #100 and explore the MoA of cretostimogene grenadenorepvec through Virtual Reality. This is an incredible opportunity to gain insights into the future of #bladdercancer therapy and learn how our pipeline and clinical trial programs can complement your practice. More details coming soon!

🗓️ Learn more here: auanet.org/AUA2024

#CGOncology #BladderCancer #CancerResearch #UroOncology #MedicalResearch #CancerResearch #ClinicalTrial #Therapeutics #DrugDevelopment #Immunotherapy #OncologyBreakthrough #TherapeuticAdvances #AUA24

CG Oncology is growing! We recently welcomed some exceptionally talented team members who will be joining with us in Attacking Bladder Cancer for a Better Tomorrow™. Welcome to CG Oncology Adrian Knoth, M.Sc, PMP, Anthony Fernandez, PharmD, MSL-BC, Davis Bauman, Shelja Patel, PharmD, RPh, BCMAS and Victoria D'Anthony. If you are interested in joining our team of intelligent and passionate team members that share our Vision, Mission and Values, please visit our Careers Page: https://lnkd.in/e-UiUYdg

Today marks another step forward in our ongoing effort to transform the treatment landscape for #bladdercancer. The first patient has been dosed in the PIVOT-006 Phase 3 trial, which is investigating cretostimogene grenadenorepvec as an investigational drug for the treatment of Intermediate-Risk, Non-Muscle Invasive Bladder Cancer (#NMIBC) following transurethral resection of the bladder tumor (#TURBT).  

With over 80,000 individuals diagnosed annually with bladder cancer in the United States, the PIVOT-006 study addresses the unmet medical need for patients facing limited treatment options. Dr. Neal Shore, MD, FACS of Carolina Urologic Research Center confirmed the potential impact of this therapy: “Cretostimogene is a novel therapy which has the potential to be a paradigm shift in how we might manage the ongoing burden of this highly recurrent aspect of bladder cancer.”
 
Learn more about the PIVOT-006 study and how CG Oncology is committed to developing novel bladder-sparing therapeutics that improve patient outcomes.

📄 Read the full release: https://bit.ly/49AOqTO 
 
#Urology #ClinicalTrials #UrothelialCancer #CancerResearch #MedicalResearch #PatientCare #Immunotherapy #Therapeutics #CGOncology #PIVOT006

	Mar '23	Sep '23	Dec '23	Mar '24	Jun '24
account payables		1.96M -	3.24M 65.32%	4.66M 43.68%	4.49M 3.59%
accumulated other comprehensive income loss	-77.69M -			0.00 -
cash and cash equivalents	-143.48M -	10.27M 107.16%	8.27M 19.54%	77.47M 837.19%	25.16M 67.52%
cash and short term investments	143.48M -	203.75M 42.00%	187.67M 7.89%	566.51M 201.86%	552.88M 2.41%
common stock		1K -		7K -	7K 0%
deferred revenue		9.11M -
deferred revenue non current
deferrred tax liabilities non current
goodwill
goodwill and intangible assets
intangible assets
inventory
long term debt		302K -	13K 95.70%	184K 1,315.38%
long term investments
net debt	143.48M -	-9.76M 106.80%	-7.44M 23.74%	-77.06M 935.81%	-24.80M 67.82%
net receivables		1K -	92K 9,100%	153K 66.30%	182K 18.95%
other assets			1 -	1 0%
other current assets		5.96M -	6.36M 6.71%	11.95M 87.94%	10.80M 9.60%
other current liabilities		422K -	10.44M 2,374.64%	5.11M 51.11%	7.13M 39.54%
other liabilities			1 -	1 0%
other non current assets	-143.48M -	1.63M 101.13%	4.69M 188.01%	53.00K 98.87%	53K 0.00%
other non current liabilities		307.90M -	244.00K 99.92%	-1 100.00%
othertotal stockholders equity		5.80M -	6.84M 17.92%	715.81M 10,361.96%	718.13M 0.32%
preferred stock	202.87M -		307.89M -
property plant equipment net		550K -	491K 10.73%	445K 9.37%	413K 7.19%
retained earnings		-113.83M -	-129.94M 14.16%	-146.87M 13.03%	-165.78M 12.87%
short term debt		215K -	569K 164.65%	220K 61.34%	237K 7.73%
short term investments	286.96M -	193.48M 32.58%	179.41M 7.27%	489.04M 172.59%	527.72M 7.91%
tax assets
tax payables
total assets		211.88M -	199.30M 5.94%	579.11M 190.57%	564.33M 2.55%
total current assets	143.48M -	209.71M 46.16%	194.12M 7.43%	578.61M 198.06%	563.86M 2.55%
total current liabilities		11.70M -	14.25M 21.80%	9.98M 29.96%	11.85M 18.72%
total debt		517K -	826K 59.77%	404K 51.09%	355K 12.13%
total investments	286.96M -	193.48M 32.58%	179.41M 7.27%	489.04M 172.59%	527.72M 7.91%
total liabilities		319.91M -	14.51M 95.46%	10.17M 29.93%	11.97M 17.73%
total liabilities and stockholders equity	125.18M -	211.88M 69.27%	199.30M 5.94%	579.11M 190.57%	564.33M 2.55%
total non current assets	-143.48M -	2.18M 101.52%	5.18M 137.80%	498.00K 90.38%	466K 6.43%
total non current liabilities		308.20M -	257.00K 99.92%	184.00K 28.40%	118K 35.87%
total stockholders equity	125.18M -	-108.02M 186.30%	184.79M 271.07%	568.94M 207.88%	552.36M 2.91%

CGON

COM:CGONCOLOGY

CG Oncology

Last Close

36.68

30/08 20:00

Market Cap

2.19B

Beta: -

Volume Today

544.38K

Avg: -

Preview